Descreva o achado como no laudo. A resposta aponta uma das categorias publicadas, com a probabilidade e o trecho que a decide.
Categorias
Reescritas a partir da fonte e citadas
I
1 de 4
Stage I
Disease confined to a single lymph node region or lymphoid structure, or a single extranodal site (IE). Modifiers (all stages): A = no B symptoms; B = B symptoms (unexplained fever, drenching night sweats, or >10% body-weight loss); E = limited contiguous extension into one adjacent extranodal site; S = splenic involvement; X = bulky disease (mass >10 cm, or a mediastinal mass exceeding one-third of the internal transverse thoracic diameter).
CondutaEarly-stage (I-II) favorable disease is treated with combined-modality therapy: a short course of ABVD chemotherapy (e.g. 2 cycles) followed by involved-site/involved-field radiotherapy.
RiscoEarly stage (I-IIA) carries an excellent prognosis, with roughly 90% 5-year overall survival.
verificadoAnn Arbor stagingWikipedia 'Ann Arbor staging', Principal stages (Stage I) + Modifiers (A/B, E, S, X). Management and survival from StatPearls NBK499969, Treatment/Prognosis ('two cycles of ABVD ... followed by ... involved-field radiation therapy'; early stages I-IIA ~90% 5-year overall survival).
II
2 de 4
Stage II
Involvement of two or more lymph node regions on the same side of the diaphragm (or localized contiguous extranodal extension, IIE).
CondutaEarly-stage (I-II) disease is treated with combined-modality therapy (ABVD chemotherapy plus involved-site radiotherapy); unfavorable features (bulky/X disease, elevated ESR, extranodal extension) prompt more chemotherapy cycles (4-6) and higher-dose radiation.
RiscoEarly favorable stage I-IIA disease has roughly 90% 5-year overall survival; unfavorable features worsen the outlook.
verificadoAnn Arbor stagingWikipedia 'Ann Arbor staging', Principal stages (Stage II); corroborated by StatPearls NBK499969, Staging ('2 or more lymph node regions on the same side of the diaphragm'). Management/prognosis from NBK499969 Treatment (combined modality; 4-6 cycles for unfavorable features) and Prognosis (~90% early-stage OS).
III
3 de 4
Stage III
Lymph node regions or lymphoid structures involved on both sides of the diaphragm; may include splenic (S) or limited contiguous extranodal (E) involvement.
CondutaAdvanced-stage disease is treated mainly with multi-agent chemotherapy (ABVD for most; escalated BEACOPP or Stanford V in selected higher-risk patients per IPS); radiotherapy is generally not beneficial.
RiscoAdvanced stage carries a less favorable prognosis than early stage; risk is further stratified by the International Prognostic Score.
verificadoAnn Arbor stagingWikipedia 'Ann Arbor staging', Principal stages (Stage III); corroborated by StatPearls NBK499969, Staging ('both sides of the diaphragm'). Management from NBK499969 Treatment (advanced-stage chemotherapy 'ABVD for most patients'; 'radiation, in general, is not beneficial'); IPS stratification noted.
IV
4 de 4
Stage IV
Diffuse or disseminated involvement of one or more extralymphatic (extranodal) organs or tissues (e.g. liver, bone marrow), beyond limited contiguous E-type extension, with or without associated nodal involvement.
CondutaTreated as advanced-stage disease with multi-agent chemotherapy (ABVD for most; escalated BEACOPP or Stanford V in selected higher-risk patients); radiotherapy is generally not beneficial.
RiscoMost extensive stage with the least favorable outlook; stage IV disease has roughly 60% 5-year overall survival.
verificadoAnn Arbor stagingWikipedia 'Ann Arbor staging', Principal stages (Stage IV); corroborated by StatPearls NBK499969, Staging ('extranodal sites beyond those designated as E'). Management/prognosis from NBK499969 Treatment (advanced-stage chemotherapy) and Prognosis ('stage IV disease ... approximately 60%' 5-year OS).
Lógica de decisão estruturada
{
"categories": [
"I",
"II",
"III",
"IV"
]
}
Referência, não é dispositivo médico. Confira a publicação primária vigente. O radiologista que assina o laudo continua autor e responsável.